Lentivirus Articles & Analysis: Older
7 news found
This spurred further studies into other viruses such as Lentivirus where the performance of SwabReady™ was equally impressive with no drop-off in viral function after 2 weeks, whilst this fell to non-detectable levels by 3 days in the control. ...
Genenta's Temferon™, a lentivirus based hematopoietic stem progenitor cell immuno gene & cell therapy enabling controlled and targeted interferon-α expression within cancers, will be discussed as a potential treatment solution for glioblastoma patients. ...
Ella Korets-Smith, Chief Business Officer of Virica Biotech, said: “There is growing demand from major industry players to use leading lentivirus technologies, like Oxford Biomedica’s LentiVector® platform, to develop cell and gene therapies. ...
Singapore-based CellVec will manufacture clinical-grade lentivirus – the first critical step in making LGR5 CAR-T cells for a first-in-human clinical trial for patients with advanced colorectal (bowel) cancer in late 2022. Lentiviruses are widely used as a tool to deliver genes of interest to cells. In this case, the lentivirus transduces (or inserts) a ...
Research has also found that exosome targeting can be achieved by the construction of a lentivirus vector and scientists at Creative Biolabs have developed an exosome targeting peptide for interested proteins fusion, producing lentivectors that are able to deliver the interested proteins into exosomes. ...
Our GMP facility in College Station, TX is designed for the rapid development, scale-up and production of Lentivirus and AAV products for clinical supply. Matica Bio offers process development, production, product release and stability assessment of viral vector products; together with the quality oversight and regulatory guidance necessary to ensure our clients’ success. ...
Our GMP facility in College Station, TX is designed for the rapid development, scale-up and production of Lentivirus and AAV products for clinical supply. Matica Bio offers process development, production, product release and stability assessment of viral vector products; together with the quality oversight and regulatory guidance necessary to ensure our clients’ success. ...